ID   PAG_BACAN               Reviewed;         764 AA.
AC   P13423; Q937W2; Q937W3; Q9F5R7; Q9KH69; Q9RQU2;
DT   01-JAN-1990, integrated into UniProtKB/Swiss-Prot.
DT   18-OCT-2001, sequence version 2.
DT   22-JUL-2015, entry version 152.
DE   RecName: Full=Protective antigen;
DE            Short=PA;
DE   AltName: Full=Anthrax toxins translocating protein;
DE   AltName: Full=PA-83;
DE            Short=PA83;
DE   Contains:
DE     RecName: Full=Protective antigen PA-20;
DE              Short=PA20;
DE   Contains:
DE     RecName: Full=Protective antigen PA-63;
DE              Short=PA63;
DE   Flags: Precursor;
GN   Name=pagA; Synonyms=pag;
GN   OrderedLocusNames=pXO1-110, BXA0164, GBAA_pXO1_0164;
OS   Bacillus anthracis.
OG   Plasmid pXO1.
OC   Bacteria; Firmicutes; Bacilli; Bacillales; Bacillaceae; Bacillus;
OC   Bacillus cereus group.
OX   NCBI_TaxID=1392;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3148491; DOI=10.1016/0378-1119(88)90439-8;
RA   Welkos S.L., Lowe J.R., Eden-Mccutchan F., Vodkin M., Leppla S.H.,
RA   Schmidt J.J.;
RT   "Sequence and analysis of the DNA encoding protective antigen of
RT   Bacillus anthracis.";
RL   Gene 69:287-300(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=28, 33, BA1024, and BA1035;
RX   PubMed=10197996;
RA   Price L.B., Hugh-Jones M., Jackson P.J., Keim P.;
RT   "Genetic diversity in the protective antigen gene of Bacillus
RT   anthracis.";
RL   J. Bacteriol. 181:2358-2362(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=V770-NP1-R / ATCC 14185;
RX   PubMed=10899854; DOI=10.1128/IAI.68.8.4549-4558.2000;
RA   Cohen S., Mendelson I., Altboum Z., Kobiler D., Elhanany E., Bino T.,
RA   Leitner M., Inbar I., Rosenberg H., Gozes Y., Barak R., Fisher M.,
RA   Kronman C., Velan B., Shafferman A.;
RT   "Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus
RT   anthracis spore vaccines protect against anthrax.";
RL   Infect. Immun. 68:4549-4558(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Sterne;
RX   PubMed=10515943;
RA   Okinaka R.T., Cloud K., Hampton O., Hoffmaster A.R., Hill K.K.,
RA   Keim P., Koehler T.M., Lamke G., Kumano S., Mahillon J., Manter D.,
RA   Martinez Y., Ricke D., Svensson R., Jackson P.J.;
RT   "Sequence and organization of pXO1, the large Bacillus anthracis
RT   plasmid harboring the anthrax toxin genes.";
RL   J. Bacteriol. 181:6509-6515(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=Ames / isolate Florida / A2012;
RX   PubMed=12004073; DOI=10.1126/science.1071837;
RA   Read T.D., Salzberg S.L., Pop M., Shumway M.F., Umayam L., Jiang L.,
RA   Holtzapple E., Busch J.D., Smith K.L., Schupp J.M., Solomon D.,
RA   Keim P., Fraser C.M.;
RT   "Comparative genome sequencing for discovery of novel polymorphisms in
RT   Bacillus anthracis.";
RL   Science 296:2028-2033(2002).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Ames ancestor;
RX   PubMed=18952800; DOI=10.1128/JB.01347-08;
RA   Ravel J., Jiang L., Stanley S.T., Wilson M.R., Decker R.S., Read T.D.,
RA   Worsham P., Keim P.S., Salzberg S.L., Fraser-Liggett C.M., Rasko D.A.;
RT   "The complete genome sequence of Bacillus anthracis Ames 'Ancestor'.";
RL   J. Bacteriol. 191:445-446(2009).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 9-751.
RC   STRAIN=Carbosap, and Ferrara;
RX   PubMed=12067380; DOI=10.1046/j.1365-2672.2002.01660.x;
RA   Adone R., Pasquali P., La Rosa G., Marianelli C., Muscillo M.,
RA   Fasanella A., Francia M., Ciuchini F.;
RT   "Sequence analysis of the genes encoding for the major virulence
RT   factors of Bacillus anthracis vaccine strain 'Carbosap'.";
RL   J. Appl. Microbiol. 93:117-121(2002).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 195-434.
RC   STRAIN=PAI;
RX   PubMed=14985634;
RA   Inoue S., Noguchi A., Tanabayashi K., Yamada A.;
RT   "Preparation of a positive control DNA for molecular diagnosis of
RT   Bacillus anthracis.";
RL   Jpn. J. Infect. Dis. 57:29-32(2004).
RN   [9]
RP   DOMAINS.
RX   PubMed=1651334;
RA   Singh Y., Klimpel K.R., Quinn C.P., Chaudhary V.K., Leppla S.H.;
RT   "The carboxyl-terminal end of protective antigen is required for
RT   receptor binding and anthrax toxin activity.";
RL   J. Biol. Chem. 266:15493-15497(1991).
RN   [10]
RP   CHARACTERIZATION.
RC   STRAIN=Sterne;
RX   PubMed=8051159;
RA   Milne J.C., Furlong D., Hanna P.C., Wall J.S., Collier R.J.;
RT   "Anthrax protective antigen forms oligomers during intoxication of
RT   mammalian cells.";
RL   J. Biol. Chem. 269:20607-20612(1994).
RN   [11]
RP   CHARACTERIZATION.
RX   PubMed=11207581; DOI=10.1046/j.1462-5822.2000.00052.x;
RA   Beauregard K.E., Collier R.J., Swanson J.A.;
RT   "Proteolytic activation of receptor-bound anthrax protective antigen
RT   on macrophages promotes its internalization.";
RL   Cell. Microbiol. 2:251-258(2000).
RN   [12]
RP   TOXIN REGULATION.
RC   STRAIN=Weybridge;
RX   PubMed=8300513;
RA   Koehler T.M., Dai Z., Kaufman-Yarbray M.;
RT   "Regulation of the Bacillus anthracis protective antigen gene: CO2 and
RT   a trans-acting element activate transcription from one of two
RT   promoters.";
RL   J. Bacteriol. 176:586-595(1994).
RN   [13]
RP   FOLDING BY PSRA.
RX   PubMed=12606539; DOI=10.1074/jbc.M301244200;
RA   Williams R.C., Rees M.L., Jacobs M.F., Pragai Z., Thwaite J.E.,
RA   Baillie L.W., Emmerson P.T., Harwood C.R.;
RT   "Production of Bacillus anthracis protective antigen is dependent on
RT   the extracellular chaperone, PrsA.";
RL   J. Biol. Chem. 278:18056-18062(2003).
RN   [14]
RP   INTERACTION WITH ANTHRAX TOXIN RECEPTOR.
RX   PubMed=14507921; DOI=10.1074/jbc.M307900200;
RA   Bradley K.A., Mogridge J., Jonah G., Rainey G.J.A., Batty S.,
RA   Young J.A.T.;
RT   "Binding of anthrax toxin to its receptor is similar to alpha
RT   integrin-ligand interactions.";
RL   J. Biol. Chem. 278:49342-49347(2003).
RN   [15]
RP   MUTAGENESIS OF 342-PHE-PHE-343 AND ASP-344.
RC   STRAIN=Sterne;
RX   PubMed=7961869;
RA   Singh Y., Klimpel K.R., Arora N., Sharma M., Leppla S.H.;
RT   "The chymotrypsin-sensitive site, FFD315, in anthrax toxin protective
RT   antigen is required for translocation of lethal factor.";
RL   J. Biol. Chem. 269:29039-29046(1994).
RN   [16]
RP   MUTAGENESIS OF DOMAIN 4 LOOPS.
RC   STRAIN=Sterne;
RX   PubMed=10085028;
RA   Varughese M., Teixeira A.V., Liu S., Leppla S.H.;
RT   "Identification of a receptor-binding region within domain 4 of the
RT   protective antigen component of anthrax toxin.";
RL   Infect. Immun. 67:1860-1865(1999).
RN   [17]
RP   MUTAGENESIS OF TRP-375; MET-379 AND LEU-381.
RC   STRAIN=Sterne;
RX   PubMed=11178978; DOI=10.1006/bbrc.2001.4320;
RA   Batra S., Gupta P., Chauhan V., Singh A., Bhatnagar R.;
RT   "Trp 346 and Leu 352 residues in protective antigen are required for
RT   the expression of anthrax lethal toxin activity.";
RL   Biochem. Biophys. Res. Commun. 281:186-192(2001).
RN   [18]
RP   MUTAGENESIS OF PHE-581; PHE-583; ILE-591; LEU-595 AND ILE-603.
RC   STRAIN=Sterne;
RX   PubMed=11554763; DOI=10.1006/bbrc.2001.5613;
RA   Ahuja N., Kumar P., Bhatnagar R.;
RT   "Hydrophobic residues Phe552, Phe554, Ile562, Leu566, and Ile574 are
RT   required for oligomerization of anthrax protective antigen.";
RL   Biochem. Biophys. Res. Commun. 287:542-549(2001).
RN   [19]
RP   MUTAGENESIS OF PRO-289.
RC   STRAIN=Sterne;
RX   PubMed=11356563; DOI=10.1111/j.1574-6968.2001.tb10646.x;
RA   Khanna H., Chopra A.P., Arora N., Chaudhry A., Singh Y.;
RT   "Role of residues constituting the 2beta1 strand of domain II in the
RT   biological activity of anthrax protective antigen.";
RL   FEMS Microbiol. Lett. 199:27-31(2001).
RN   [20]
RP   MUTAGENESIS OF GLN-512; ASP-541; LEU-543 AND ARG-621.
RX   PubMed=11222612; DOI=10.1128/JB.183.6.2111-2116.2001;
RA   Mogridge J., Mourez M., Collier R.J.;
RT   "Involvement of domain 3 in oligomerization by the protective antigen
RT   moiety of anthrax toxin.";
RL   J. Bacteriol. 183:2111-2116(2001).
RN   [21]
RP   MUTAGENESIS OF LYS-426; ASP-454 AND PHE-456.
RX   PubMed=11113126; DOI=10.1074/jbc.M008309200;
RA   Sellman B.R., Nassi S., Collier R.J.;
RT   "Point mutations in anthrax protective antigen that block
RT   translocation.";
RL   J. Biol. Chem. 276:8371-8376(2001).
RN   [22]
RP   MUTAGENESIS OF PRO-213; LEU-216; PHE-231; LEU-232; PRO-234; ILE-236;
RP   ILE-239; TRP-255 AND PHE-265.
RC   STRAIN=Sterne;
RX   PubMed=12117959; DOI=10.1128/IAI.70.8.4477-4484.2002;
RA   Chauhan V., Bhatnagar R.;
RT   "Identification of amino acid residues of anthrax protective antigen
RT   involved in binding with lethal factor.";
RL   Infect. Immun. 70:4477-4484(2002).
RN   [23]
RP   MUTAGENESIS OF ILE-393; THR-409; SER-411; THR-422; LYS-426; ASN-428;
RP   TYR-440; ASN-451; ASP-454 AND PHE-456.
RX   PubMed=14623961; DOI=10.1073/pnas.2436299100;
RA   Mourez M., Yan M., Lacy D.B., Dillon L., Bentsen L., Marpoe A.,
RA   Maurin C., Hotze E., Wigelsworth D., Pimental R.-A., Ballard J.D.,
RA   Collier R.J., Tweten R.K.;
RT   "Mapping dominant-negative mutations of anthrax protective antigen by
RT   scanning mutagenesis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:13803-13808(2003).
RN   [24]
RP   MUTAGENESIS OF ASN-686; LYS-708; LYS-709; TYR-710; ASN-711; ASP-712;
RP   LYS-713; LEU-714; PRO-715; LEU-716; TYR-717; ILE-718; ASN-720; PRO-721
RP   AND ASN-722.
RX   PubMed=12771151; DOI=10.1074/jbc.M301154200;
RA   Rosovitz M.J., Schuck P., Varughese M., Chopra A.P., Mehra V.,
RA   Singh Y., McGinnis L.M., Leppla S.H.;
RT   "Alanine-scanning mutations in domain 4 of anthrax toxin protective
RT   antigen reveal residues important for binding to the cellular receptor
RT   and to a neutralizing monoclonal antibody.";
RL   J. Biol. Chem. 278:30936-30944(2003).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS).
RX   PubMed=9039918; DOI=10.1038/385833a0;
RA   Petosa C., Collier R.J., Klimpel K.R., Leppla S.H., Liddington R.C.;
RT   "Crystal structure of the anthrax toxin protective antigen.";
RL   Nature 385:833-838(1997).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 30-764 IN COMPLEX WITH
RP   ANTXR2.
RX   PubMed=15243628; DOI=10.1038/nature02763;
RA   Santelli E., Bankston L.A., Leppla S.H., Liddington R.C.;
RT   "Crystal structure of a complex between anthrax toxin and its host
RT   cell receptor.";
RL   Nature 430:905-908(2004).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (4.3 ANGSTROMS) OF 203-764 IN COMPLEX WITH
RP   ANTXR2.
RX   PubMed=15326297; DOI=10.1073/pnas.0405405101;
RA   Lacy D.B., Wigelsworth D.J., Melnyk R.A., Harrison S.C., Collier R.J.;
RT   "Structure of heptameric protective antigen bound to an anthrax toxin
RT   receptor: a role for receptor in pH-dependent pore formation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:13147-13151(2004).
RN   [28]
RP   REVIEW.
RX   PubMed=11544370; DOI=10.1146/annurev.micro.55.1.647;
RA   Mock M., Fouet A.;
RT   "Anthrax.";
RL   Annu. Rev. Microbiol. 55:647-671(2001).
CC   -!- FUNCTION: One of the three proteins composing the anthrax toxin,
CC       the agent which infects many mammalian species and that may cause
CC       death. PA binds to a receptor (ATR) in sensitive eukaryotic cells,
CC       thereby facilitating the translocation of the enzymatic toxin
CC       components, edema factor and lethal factor, across the target cell
CC       membrane. PA associated with LF causes death when injected, PA
CC       associated with EF produces edema. PA induces immunity to
CC       infection with anthrax.
CC   -!- SUBUNIT: Anthrax toxins are composed of three distinct proteins, a
CC       protective antigen (PA), a lethal factor (LF) and an edema factor
CC       (EF). None of these is toxic by itself. PA+LF forms the lethal
CC       toxin (LeTx); PA+EF forms the edema toxin (EdTx). PA-63 forms
CC       heptamers and this oligomerization is required for LF or EF
CC       binding. This complex is endocytosed by the host. Once activated,
CC       at low pH, the heptamer undergoes conformational changes and
CC       converts from prepore to pore inserted in the membrane, forming
CC       cation-selective channels and triggering the release of LF and EF
CC       in the host cytoplasm. {ECO:0000269|PubMed:15243628,
CC       ECO:0000269|PubMed:15326297}.
CC   -!- INTERACTION:
CC       Self; NbExp=2; IntAct=EBI-456868, EBI-456868;
CC       Q9H6X2-2:ANTXR1 (xeno); NbExp=3; IntAct=EBI-456868, EBI-905659;
CC       P58335:ANTXR2 (xeno); NbExp=7; IntAct=EBI-456868, EBI-456840;
CC       P15917:lef; NbExp=5; IntAct=EBI-456868, EBI-456923;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space. Note=Secreted
CC       through the Sec-dependent secretion pathway. Therefore, PA is
CC       translocated across the membrane in an unfolded state and then it
CC       is folded into its native configuration on the trans side of the
CC       membrane, prior to its release to the environment. PA requires the
CC       extracellular chaperone PrsA for efficient folding.
CC   -!- DOMAIN: The molecule is folded into four functional domains. Each
CC       domain is required for a particular step in the toxicity process.
CC       Domain 1 contains two calcium ions and the proteolytic activation
CC       site. Cleavage of the PA monomer releases the subdomain 1a, which
CC       is the N-terminal fragment of 20-kDa (PA20). The subdomain 1b is
CC       part of the remaining 63-kDa fragment (PA63) and contains the
CC       binding sites for LP and EF. Domain 2 is a beta-barrel core
CC       containing a large flexible loop that has been implicated in
CC       membrane insertion and pore formation. There is a chymotrypsin
CC       cleavage site in this loop that is required for toxicity. Domain 3
CC       has a hydrophobic patch thought to be involved in protein-protein
CC       interactions. Domain 4 appears to be a separate domain and shows
CC       limited contact with the other three domains: it would swing out
CC       of the way during membrane insertion. It is required for binding
CC       to the receptor; the small loop is involved in receptor
CC       recognition. {ECO:0000269|PubMed:1651334}.
CC   -!- PTM: Proteolytic activation by furin or a furin-like protease
CC       cleaves the protein in two parts, PA-20 and PA-63; the latter is
CC       the mature protein. The cleavage occurs at the cell surface and
CC       probably in the serum of infected animals as well; both native and
CC       cleaved PA are able to bind to the cell receptor. The release of
CC       PA20 from the remaining receptor-bound PA63 exposes the binding
CC       site for EF and LF, and promotes oligomerization and
CC       internalization of the protein.
CC   -!- MISCELLANEOUS: In PubMed:10085028 multiple mutagenesis experiments
CC       were performed that showed that the residues present in the small
CC       loop of domain 4, and not the ones in the large loop, are involved
CC       in receptor recognition. In PubMed:14623961 high-throughput
CC       scanning mutagenesis experiments were performed in which all
CC       residues of PA-63 were mutated into Cys. Dominantly negative (DN)
CC       mutants were all clustered in domain 2. DN mutants prevent the
CC       conformational transition of PA-63 from the prepore to the pore
CC       state.
CC   -!- SIMILARITY: Belongs to the bacterial binary toxin family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M22589; AAA22637.1; -; Genomic_DNA.
DR   EMBL; AF306778; AAG24446.1; -; Genomic_DNA.
DR   EMBL; AF306779; AAG24447.1; -; Genomic_DNA.
DR   EMBL; AF306780; AAG24448.1; -; Genomic_DNA.
DR   EMBL; AF306781; AAG24449.1; -; Genomic_DNA.
DR   EMBL; AF306782; AAG24450.1; -; Genomic_DNA.
DR   EMBL; AF306783; AAG24451.1; -; Genomic_DNA.
DR   EMBL; AF268967; AAF86457.1; -; Genomic_DNA.
DR   EMBL; AF065404; AAD32414.1; -; Genomic_DNA.
DR   EMBL; AE011190; AAM26109.1; -; Genomic_DNA.
DR   EMBL; AE017336; AAT28905.2; -; Genomic_DNA.
DR   EMBL; AJ413936; CAC93934.1; -; Genomic_DNA.
DR   EMBL; AJ413937; CAC93935.1; -; Genomic_DNA.
DR   EMBL; AB125961; BAD14937.1; -; Genomic_DNA.
DR   PIR; I39934; I39934.
DR   RefSeq; NP_052806.1; NC_001496.1.
DR   RefSeq; WP_000746486.1; NZ_KN050652.1.
DR   RefSeq; WP_000746487.1; NZ_JTAQ01000005.1.
DR   RefSeq; WP_000746488.1; NZ_CP009463.1.
DR   RefSeq; YP_009076489.1; NG_035311.1.
DR   RefSeq; YP_009076589.1; NG_036934.1.
DR   RefSeq; YP_009083333.1; NG_036935.1.
DR   RefSeq; YP_009083334.1; NG_036936.1.
DR   RefSeq; YP_009083335.1; NG_036937.1.
DR   RefSeq; YP_009083336.1; NG_036938.1.
DR   RefSeq; YP_009083337.1; NG_035343.1.
DR   PDB; 1ACC; X-ray; 2.10 A; A=30-764.
DR   PDB; 1T6B; X-ray; 2.50 A; X=30-764.
DR   PDB; 1TX5; Model; -; C=30-764.
DR   PDB; 1TZN; X-ray; 4.30 A; A/B/C/D/E/F/G/H/I/J/K/L/M/O=203-764.
DR   PDB; 1TZO; X-ray; 3.60 A; A/B/C/D/E/F/G/H/I/J/K/L/M/O=203-764.
DR   PDB; 1V36; Model; -; A/B/C/D/E/F/G=197-764.
DR   PDB; 3ETB; X-ray; 3.80 A; J/K/L/M=621-764.
DR   PDB; 3INO; X-ray; 1.95 A; A/B=624-764.
DR   PDB; 3J9C; EM; 2.90 A; A=203-764.
DR   PDB; 3KWV; X-ray; 3.10 A; A/B/D/E=197-764.
DR   PDB; 3MHZ; X-ray; 1.70 A; A=30-764.
DR   PDB; 3Q8A; X-ray; 3.13 A; A=30-764.
DR   PDB; 3Q8B; X-ray; 2.00 A; A=30-764.
DR   PDB; 3Q8C; X-ray; 2.85 A; A=30-764.
DR   PDB; 3Q8E; X-ray; 2.10 A; A=30-764.
DR   PDB; 3Q8F; X-ray; 2.10 A; A=30-764.
DR   PDB; 3TEW; X-ray; 1.45 A; A=30-764.
DR   PDB; 3TEX; X-ray; 1.70 A; A=30-764.
DR   PDB; 3TEY; X-ray; 2.12 A; A=30-764.
DR   PDB; 3TEZ; X-ray; 1.83 A; A=30-764.
DR   PDB; 4EE2; X-ray; 1.91 A; A=30-764.
DR   PDB; 4H2A; X-ray; 1.62 A; A=30-764.
DR   PDB; 4NAM; X-ray; 1.70 A; A=30-764.
DR   PDBsum; 1ACC; -.
DR   PDBsum; 1T6B; -.
DR   PDBsum; 1TX5; -.
DR   PDBsum; 1TZN; -.
DR   PDBsum; 1TZO; -.
DR   PDBsum; 1V36; -.
DR   PDBsum; 3ETB; -.
DR   PDBsum; 3INO; -.
DR   PDBsum; 3J9C; -.
DR   PDBsum; 3KWV; -.
DR   PDBsum; 3MHZ; -.
DR   PDBsum; 3Q8A; -.
DR   PDBsum; 3Q8B; -.
DR   PDBsum; 3Q8C; -.
DR   PDBsum; 3Q8E; -.
DR   PDBsum; 3Q8F; -.
DR   PDBsum; 3TEW; -.
DR   PDBsum; 3TEX; -.
DR   PDBsum; 3TEY; -.
DR   PDBsum; 3TEZ; -.
DR   PDBsum; 4EE2; -.
DR   PDBsum; 4H2A; -.
DR   PDBsum; 4NAM; -.
DR   ProteinModelPortal; P13423; -.
DR   SMR; P13423; 45-764.
DR   DIP; DIP-29841N; -.
DR   IntAct; P13423; 15.
DR   MINT; MINT-7014733; -.
DR   BindingDB; P13423; -.
DR   ChEMBL; CHEMBL3301396; -.
DR   DrugBank; DB08902; Raxibacumab.
DR   TCDB; 1.C.42.1.1; the channel-forming bacillus anthracis protective antigen (bapa) family.
DR   EnsemblBacteria; AAT28905; AAT28905; GBAA_pXO1_0164.
DR   GeneID; 3361714; -.
DR   KEGG; bar:GBAA_pXO1_0164; -.
DR   KEGG; pg:3361714; -.
DR   PATRIC; 24662127; VBIBacAnt106580_0153.
DR   eggNOG; NOG284171; -.
DR   HOGENOM; HOG000034566; -.
DR   KO; K11030; -.
DR   OMA; ISTNEHA; -.
DR   OrthoDB; EOG6D5FXS; -.
DR   BioCyc; ANTHRA:GBAA_PXO1_0164-MONOMER; -.
DR   BioCyc; BANT261594:GJ7F-5750-MONOMER; -.
DR   Reactome; REACT_264618; Uptake and function of anthrax toxins.
DR   EvolutionaryTrace; P13423; -.
DR   PMAP-CutDB; P13423; -.
DR   PRO; PR:P13423; -.
DR   Proteomes; UP000000594; Plasmid pXO1.
DR   GO; GO:0010008; C:endosome membrane; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0009405; P:pathogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0051260; P:protein homooligomerization; IEA:InterPro.
DR   Gene3D; 2.60.120.240; -; 1.
DR   Gene3D; 2.60.40.810; -; 1.
DR   Gene3D; 3.10.20.110; -; 1.
DR   Gene3D; 3.90.182.10; -; 1.
DR   InterPro; IPR003896; Bacterial_exotoxin_B.
DR   InterPro; IPR023125; Bacterial_exotoxin_B_Fd-like.
DR   InterPro; IPR011658; PA14.
DR   InterPro; IPR027441; PA_dom4.
DR   InterPro; IPR027439; PA_heptamer_dom.
DR   Pfam; PF03495; Binary_toxB; 1.
DR   Pfam; PF07691; PA14; 1.
DR   PRINTS; PR01391; BINARYTOXINB.
DR   SMART; SM00758; PA14; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Cleavage on pair of basic residues;
KW   Complete proteome; Metal-binding; Plasmid; Reference proteome;
KW   Secreted; Signal; Toxin; Virulence.
FT   SIGNAL        1     29
FT   CHAIN        30    764       Protective antigen.
FT                                /FTId=PRO_0000021996.
FT   CHAIN        30    196       Protective antigen PA-20.
FT                                /FTId=PRO_0000021997.
FT   CHAIN       197    764       Protective antigen PA-63.
FT                                /FTId=PRO_0000021998.
FT   REGION       30    287       Domain 1, calcium-binding; LF and EF
FT                                binding sites.
FT   REGION      288    516       Domain 2, membrane insertion and
FT                                heptamerization.
FT   REGION      517    624       Domain 3, heptamerization.
FT   REGION      625    764       Domain 4, binding to the receptor.
FT   METAL       206    206       Calcium.
FT   METAL       208    208       Calcium.
FT   METAL       210    210       Calcium.
FT   METAL       217    217       Calcium.
FT   SITE        196    197       Cleavage; by furin.
FT   SITE        343    344       Cleavage; by chymotrypsin; required for
FT                                translocation of LF and EF.
FT   SITE        712    712       Essential for binding to cell receptor.
FT   VARIANT     295    295       M -> I (in strain: PAI).
FT   VARIANT     392    392       N -> D (in strain: PAI).
FT   VARIANT     560    560       F -> L (in Sverdlovsk sample).
FT   VARIANT     565    565       P -> S (in strain: BA1024).
FT   VARIANT     600    600       A -> V (in strain: BA1024, V770-NP1-R,
FT                                Carbosap and Ferrara).
FT   MUTAGEN     213    213       P->A: Decrease in the ability to bind to
FT                                LF and partially toxic at high
FT                                concentrations.
FT                                {ECO:0000269|PubMed:12117959}.
FT   MUTAGEN     216    216       L->A: Decrease in the ability to bind to
FT                                LF and partially toxic at high
FT                                concentrations.
FT                                {ECO:0000269|PubMed:12117959}.
FT   MUTAGEN     231    231       F->A: Loss of ability to bind to LF and
FT                                completely nontoxic.
FT                                {ECO:0000269|PubMed:12117959}.
FT   MUTAGEN     232    232       L->A: Loss of ability to bind to LF and
FT                                completely nontoxic.
FT                                {ECO:0000269|PubMed:12117959}.
FT   MUTAGEN     234    234       P->A: Loss of ability to bind to LF and
FT                                completely nontoxic.
FT                                {ECO:0000269|PubMed:12117959}.
FT   MUTAGEN     236    236       I->A: Loss of ability to bind to LF and
FT                                completely nontoxic.
FT                                {ECO:0000269|PubMed:12117959}.
FT   MUTAGEN     239    239       I->A: Decrease in the ability to bind to
FT                                LF and partially toxic at high
FT                                concentrations.
FT                                {ECO:0000269|PubMed:12117959}.
FT   MUTAGEN     255    255       W->A: No effect on LF-binding ability and
FT                                as toxic as the wild-type.
FT                                {ECO:0000269|PubMed:12117959}.
FT   MUTAGEN     265    265       F->A: No effect on LF-binding ability and
FT                                as toxic as the wild-type.
FT                                {ECO:0000269|PubMed:12117959}.
FT   MUTAGEN     289    289       P->A: Reduced toxicity in combination
FT                                with lethal factor. Decreased membrane
FT                                insertion and translocation of LF.
FT                                {ECO:0000269|PubMed:11356563}.
FT   MUTAGEN     342    344       FFD->AAA: Decrease in toxicity probably
FT                                due to slow translocation of LF.
FT                                {ECO:0000269|PubMed:10085028}.
FT   MUTAGEN     342    343       Missing: Loss of toxicity probably due to
FT                                loss of capability to translocate LF.
FT                                {ECO:0000269|PubMed:7961869}.
FT   MUTAGEN     342    342       F->C: Loss of toxicity probably due to
FT                                loss of capability to translocate LF.
FT                                {ECO:0000269|PubMed:10085028}.
FT   MUTAGEN     344    344       D->A: Decrease in toxicity probably due
FT                                to slow translocation of LF.
FT                                {ECO:0000269|PubMed:7961869}.
FT   MUTAGEN     375    375       W->A: Loss of toxicity probably due to
FT                                faulty membrane insertion or
FT                                translocation of LF/EF into the cytosol.
FT                                {ECO:0000269|PubMed:11178978}.
FT   MUTAGEN     379    379       M->A: No effect.
FT                                {ECO:0000269|PubMed:11178978}.
FT   MUTAGEN     381    381       L->A: Loss of toxicity probably due to
FT                                faulty membrane insertion or
FT                                translocation of LF/EF into the cytosol.
FT                                {ECO:0000269|PubMed:11178978}.
FT   MUTAGEN     393    393       I->C: Loss of capability to undergo
FT                                conformational changes that lead to pore
FT                                formation and translocation.
FT                                {ECO:0000269|PubMed:14623961}.
FT   MUTAGEN     409    409       T->C: Loss of capability to undergo
FT                                conformational changes that lead to pore
FT                                formation and translocation.
FT                                {ECO:0000269|PubMed:14623961}.
FT   MUTAGEN     411    411       S->C: Loss of capability to undergo
FT                                conformational changes that lead to pore
FT                                formation and translocation.
FT                                {ECO:0000269|PubMed:14623961}.
FT   MUTAGEN     422    422       T->C: Loss of capability to undergo
FT                                conformational changes that lead to pore
FT                                formation and translocation.
FT                                {ECO:0000269|PubMed:14623961}.
FT   MUTAGEN     426    426       K->A,D: Loss of capability to undergo
FT                                conformational changes that lead to pore
FT                                formation and translocation.
FT                                {ECO:0000269|PubMed:11113126,
FT                                ECO:0000269|PubMed:14623961}.
FT   MUTAGEN     428    428       N->C: Loss of capability to undergo
FT                                conformational changes that lead to pore
FT                                formation and translocation.
FT                                {ECO:0000269|PubMed:14623961}.
FT   MUTAGEN     440    440       Y->C: Loss of capability to undergo
FT                                conformational changes that lead to pore
FT                                formation and translocation.
FT                                {ECO:0000269|PubMed:14623961}.
FT   MUTAGEN     451    451       N->C: Loss of capability to undergo
FT                                conformational changes that lead to pore
FT                                formation and translocation.
FT                                {ECO:0000269|PubMed:14623961}.
FT   MUTAGEN     454    454       D->A,K: Loss of capability to undergo
FT                                conformational changes that lead to pore
FT                                formation and translocation.
FT                                {ECO:0000269|PubMed:11113126,
FT                                ECO:0000269|PubMed:14623961}.
FT   MUTAGEN     456    456       F->A: Loss of capability to undergo
FT                                conformational changes that lead to pore
FT                                formation and translocation.
FT                                {ECO:0000269|PubMed:11113126,
FT                                ECO:0000269|PubMed:14623961}.
FT   MUTAGEN     512    512       Q->A: Loss of heptamerization capability.
FT                                {ECO:0000269|PubMed:11222612}.
FT   MUTAGEN     541    541       D->A: Loss of heptamerization capability.
FT                                {ECO:0000269|PubMed:11222612}.
FT   MUTAGEN     543    543       L->A: Decrease in heptamerization
FT                                capability.
FT                                {ECO:0000269|PubMed:11222612}.
FT   MUTAGEN     581    581       F->A: Loss of toxicity due to defective
FT                                oligomerization.
FT                                {ECO:0000269|PubMed:11554763}.
FT   MUTAGEN     583    583       F->A: Decrease in toxicity due to
FT                                defective oligomerization.
FT                                {ECO:0000269|PubMed:11554763}.
FT   MUTAGEN     591    591       I->A: Loss of toxicity due to defective
FT                                oligomerization.
FT                                {ECO:0000269|PubMed:11554763}.
FT   MUTAGEN     595    595       L->A: Loss of toxicity due to defective
FT                                oligomerization.
FT                                {ECO:0000269|PubMed:11554763}.
FT   MUTAGEN     603    603       I->A: Loss of toxicity due to defective
FT                                oligomerization.
FT                                {ECO:0000269|PubMed:11554763}.
FT   MUTAGEN     621    621       R->A: No effect.
FT                                {ECO:0000269|PubMed:11222612}.
FT   MUTAGEN     686    686       N->A: Decrease in toxicity due to
FT                                decrease in cell binding.
FT                                {ECO:0000269|PubMed:12771151}.
FT   MUTAGEN     708    708       K->A: No effect on toxicity.
FT                                {ECO:0000269|PubMed:12771151}.
FT   MUTAGEN     709    709       K->A: Slight decrease in toxicity.
FT                                {ECO:0000269|PubMed:12771151}.
FT   MUTAGEN     710    710       Y->A: Great decrease in toxicity due to
FT                                decrease in cell binding.
FT                                {ECO:0000269|PubMed:12771151}.
FT   MUTAGEN     711    711       N->A: Loss of toxicity due to decrease in
FT                                cell binding.
FT                                {ECO:0000269|PubMed:12771151}.
FT   MUTAGEN     712    712       D->A: Loss of toxicity due to decrease in
FT                                cell binding.
FT                                {ECO:0000269|PubMed:12771151}.
FT   MUTAGEN     713    713       K->A: No effect on toxicity.
FT                                {ECO:0000269|PubMed:12771151}.
FT   MUTAGEN     714    714       L->A: No effect on toxicity.
FT                                {ECO:0000269|PubMed:12771151}.
FT   MUTAGEN     715    715       P->A: Great decrease in toxicity due to
FT                                decrease in cell binding.
FT                                {ECO:0000269|PubMed:12771151}.
FT   MUTAGEN     716    716       L->A: Decrease in toxicity due to
FT                                decrease in cell binding.
FT                                {ECO:0000269|PubMed:12771151}.
FT   MUTAGEN     717    717       Y->A: No effect on toxicity.
FT                                {ECO:0000269|PubMed:12771151}.
FT   MUTAGEN     718    718       I->A: Decrease in toxicity due to
FT                                decrease in cell binding.
FT                                {ECO:0000269|PubMed:12771151}.
FT   MUTAGEN     719    719       S->A: No effect on toxicity.
FT                                {ECO:0000269|PubMed:10085028}.
FT   MUTAGEN     720    720       N->A: No effect on toxicity.
FT                                {ECO:0000269|PubMed:12771151}.
FT   MUTAGEN     721    721       P->A: No effect on toxicity.
FT                                {ECO:0000269|PubMed:12771151}.
FT   MUTAGEN     722    722       N->A: No effect on toxicity.
FT                                {ECO:0000269|PubMed:12771151}.
FT   CONFLICT    314    314       Q -> E (in Ref. 1; AAA22637).
FT                                {ECO:0000305}.
FT   HELIX        41     44       {ECO:0000244|PDB:4H2A}.
FT   STRAND       47     55       {ECO:0000244|PDB:3TEW}.
FT   STRAND       60     71       {ECO:0000244|PDB:3TEW}.
FT   HELIX        76     78       {ECO:0000244|PDB:3TEW}.
FT   HELIX        84     86       {ECO:0000244|PDB:3TEW}.
FT   STRAND       91     99       {ECO:0000244|PDB:3TEW}.
FT   STRAND      104    110       {ECO:0000244|PDB:3TEW}.
FT   HELIX       113    115       {ECO:0000244|PDB:3TEW}.
FT   STRAND      116    120       {ECO:0000244|PDB:3TEW}.
FT   STRAND      123    129       {ECO:0000244|PDB:3TEW}.
FT   STRAND      135    137       {ECO:0000244|PDB:3TEW}.
FT   STRAND      142    150       {ECO:0000244|PDB:3TEW}.
FT   STRAND      155    159       {ECO:0000244|PDB:3TEW}.
FT   STRAND      162    166       {ECO:0000244|PDB:3TEW}.
FT   STRAND      168    170       {ECO:0000244|PDB:1ACC}.
FT   STRAND      172    174       {ECO:0000244|PDB:3TEW}.
FT   HELIX       177    179       {ECO:0000244|PDB:3TEW}.
FT   STRAND      186    188       {ECO:0000244|PDB:3TEW}.
FT   STRAND      191    193       {ECO:0000244|PDB:4H2A}.
FT   STRAND      199    201       {ECO:0000244|PDB:3TEW}.
FT   STRAND      210    212       {ECO:0000244|PDB:3TEW}.
FT   HELIX       214    219       {ECO:0000244|PDB:3TEW}.
FT   STRAND      221    225       {ECO:0000244|PDB:3TEW}.
FT   STRAND      230    234       {ECO:0000244|PDB:3TEW}.
FT   HELIX       237    240       {ECO:0000244|PDB:3TEW}.
FT   TURN        241    244       {ECO:0000244|PDB:3TEW}.
FT   STRAND      255    258       {ECO:0000244|PDB:3Q8A}.
FT   STRAND      259    262       {ECO:0000244|PDB:3TEW}.
FT   HELIX       264    269       {ECO:0000244|PDB:3TEW}.
FT   HELIX       278    281       {ECO:0000244|PDB:3TEW}.
FT   STRAND      291    302       {ECO:0000244|PDB:3TEW}.
FT   STRAND      318    326       {ECO:0000244|PDB:3TEW}.
FT   STRAND      330    332       {ECO:0000244|PDB:3KWV}.
FT   STRAND      357    363       {ECO:0000244|PDB:3TEW}.
FT   STRAND      369    371       {ECO:0000244|PDB:3TEW}.
FT   HELIX       375    379       {ECO:0000244|PDB:3TEW}.
FT   STRAND      386    397       {ECO:0000244|PDB:3TEW}.
FT   STRAND      399    401       {ECO:0000244|PDB:3TEW}.
FT   STRAND      403    405       {ECO:0000244|PDB:4EE2}.
FT   STRAND      410    414       {ECO:0000244|PDB:3TEW}.
FT   TURN        415    417       {ECO:0000244|PDB:3TEW}.
FT   STRAND      418    423       {ECO:0000244|PDB:3TEW}.
FT   STRAND      438    441       {ECO:0000244|PDB:3TEW}.
FT   STRAND      448    451       {ECO:0000244|PDB:3TEW}.
FT   STRAND      456    458       {ECO:0000244|PDB:3KWV}.
FT   STRAND      461    464       {ECO:0000244|PDB:3TEW}.
FT   HELIX       465    474       {ECO:0000244|PDB:3TEW}.
FT   STRAND      476    481       {ECO:0000244|PDB:3TEW}.
FT   STRAND      487    492       {ECO:0000244|PDB:3TEW}.
FT   TURN        493    496       {ECO:0000244|PDB:3TEW}.
FT   STRAND      497    505       {ECO:0000244|PDB:3TEW}.
FT   HELIX       506    508       {ECO:0000244|PDB:3TEW}.
FT   HELIX       510    516       {ECO:0000244|PDB:3TEW}.
FT   STRAND      517    522       {ECO:0000244|PDB:3TEW}.
FT   TURN        524    527       {ECO:0000244|PDB:3TEW}.
FT   STRAND      530    535       {ECO:0000244|PDB:3TEW}.
FT   HELIX       542    546       {ECO:0000244|PDB:3TEW}.
FT   HELIX       552    560       {ECO:0000244|PDB:3TEW}.
FT   STRAND      565    568       {ECO:0000244|PDB:3MHZ}.
FT   HELIX       576    578       {ECO:0000244|PDB:3TEW}.
FT   STRAND      579    583       {ECO:0000244|PDB:3TEW}.
FT   HELIX       585    597       {ECO:0000244|PDB:3TEW}.
FT   HELIX       603    605       {ECO:0000244|PDB:3TEW}.
FT   TURN        607    609       {ECO:0000244|PDB:3TEW}.
FT   STRAND      611    613       {ECO:0000244|PDB:3MHZ}.
FT   STRAND      617    622       {ECO:0000244|PDB:3TEW}.
FT   STRAND      625    627       {ECO:0000244|PDB:3TEW}.
FT   STRAND      633    636       {ECO:0000244|PDB:3TEW}.
FT   HELIX       638    644       {ECO:0000244|PDB:3TEW}.
FT   STRAND      648    652       {ECO:0000244|PDB:3TEW}.
FT   STRAND      655    658       {ECO:0000244|PDB:3TEW}.
FT   HELIX       662    666       {ECO:0000244|PDB:3TEW}.
FT   STRAND      668    676       {ECO:0000244|PDB:3TEW}.
FT   STRAND      678    680       {ECO:0000244|PDB:3KWV}.
FT   STRAND      682    684       {ECO:0000244|PDB:3TEW}.
FT   HELIX       689    691       {ECO:0000244|PDB:4EE2}.
FT   STRAND      695    697       {ECO:0000244|PDB:3TEW}.
FT   TURN        699    701       {ECO:0000244|PDB:3KWV}.
FT   STRAND      703    708       {ECO:0000244|PDB:3TEW}.
FT   TURN        709    713       {ECO:0000244|PDB:3TEW}.
FT   STRAND      723    731       {ECO:0000244|PDB:3TEW}.
FT   HELIX       732    734       {ECO:0000244|PDB:3TEW}.
FT   STRAND      741    743       {ECO:0000244|PDB:1ACC}.
FT   STRAND      753    759       {ECO:0000244|PDB:3TEW}.
FT   HELIX       760    763       {ECO:0000244|PDB:3TEW}.
SQ   SEQUENCE   764 AA;  85811 MW;  3AE1EFBF48FAA03F CRC64;
     MKKRKVLIPL MALSTILVSS TGNLEVIQAE VKQENRLLNE SESSSQGLLG YYFSDLNFQA
     PMVVTSSTTG DLSIPSSELE NIPSENQYFQ SAIWSGFIKV KKSDEYTFAT SADNHVTMWV
     DDQEVINKAS NSNKIRLEKG RLYQIKIQYQ RENPTEKGLD FKLYWTDSQN KKEVISSDNL
     QLPELKQKSS NSRKKRSTSA GPTVPDRDND GIPDSLEVEG YTVDVKNKRT FLSPWISNIH
     EKKGLTKYKS SPEKWSTASD PYSDFEKVTG RIDKNVSPEA RHPLVAAYPI VHVDMENIIL
     SKNEDQSTQN TDSQTRTISK NTSTSRTHTS EVHGNAEVHA SFFDIGGSVS AGFSNSNSST
     VAIDHSLSLA GERTWAETMG LNTADTARLN ANIRYVNTGT APIYNVLPTT SLVLGKNQTL
     ATIKAKENQL SQILAPNNYY PSKNLAPIAL NAQDDFSSTP ITMNYNQFLE LEKTKQLRLD
     TDQVYGNIAT YNFENGRVRV DTGSNWSEVL PQIQETTARI IFNGKDLNLV ERRIAAVNPS
     DPLETTKPDM TLKEALKIAF GFNEPNGNLQ YQGKDITEFD FNFDQQTSQN IKNQLAELNA
     TNIYTVLDKI KLNAKMNILI RDKRFHYDRN NIAVGADESV VKEAHREVIN SSTEGLLLNI
     DKDIRKILSG YIVEIEDTEG LKEVINDRYD MLNISSLRQD GKTFIDFKKY NDKLPLYISN
     PNYKVNVYAV TKENTIINPS ENGDTSTNGI KKILIFSKKG YEIG
//
